Stem cell-based and mesenchymal stem cell derivatives for coronavirus treatment

Area of Science:

• Regenerative Medicine
• Immunology
• Infectious Diseases

Background:

• COVID-19, a severe pneumonia caused by SARS-CoV-2, emerged in 2019.
• It is the third most common human coronavirus infection.
• Severe cases involve acute respiratory distress.

Purpose of the Study:

• To review the auxiliary role of mesenchymal stem cells (MSCs) and their derivatives in managing COVID-19.
• To highlight MSCs' potential in mitigating inflammatory processes in SARS-CoV-2 infections.
• To summarize recent clinical trials involving MSC-based therapies for COVID-19.

Main Methods:

• Literature review of studies on MSCs and their derivatives for respiratory infections.
• Analysis of MSC mechanisms in modulating immune response and promoting tissue repair.
• Compilation of data from clinical trials investigating MSC-based treatments for COVID-19.

Main Results:

• MSCs and their derivatives demonstrate significant anti-inflammatory effects.
• These therapies help prevent immune system overactivation.
• MSC treatment improves the lung microenvironment and promotes endogenous repair post-SARS-CoV-2 infection.

Conclusions:

• Mesenchymal stem cells (MSCs) and their derivatives represent a safe and effective auxiliary treatment for COVID-19.
• Their immunomodulatory and regenerative properties are crucial for managing severe respiratory infections.
• Further clinical trials are warranted to establish MSC-based therapies as a standard treatment for COVID-19.